APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neutropenia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neutropenia Drugs Market Outlook and Growth Opportunities 2026

26 December 2025194 pages

Choose your research edition.

Industry ResearchNeutropenia Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Neutropenia Drugs Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Neutropenia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neutropenia Drugs Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Neutropenia Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Neutropenia Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neutropenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neutropenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neutropenia Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neutropenia Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neutropenia Drugs market include Apotex Inc., Biogenomics Limited, Cellerant Therapeutics, Inc., Coherus BioSciences, Inc., Dr. Reddy’s Laboratories Limited, Ligand Pharmaceuticals, Inc., NAL Pharmaceuticals Ltd., Prolong Pharmaceuticals, LLC and Richter Gedeon Nyrt., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neutropenia Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neutropenia Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neutropenia Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neutropenia Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Neutropenia Drugs Segment by Company

Apotex Inc.

Biogenomics Limited

Cellerant Therapeutics, Inc.

Coherus BioSciences, Inc.

Dr. Reddy’s Laboratories Limited

Ligand Pharmaceuticals, Inc.

NAL Pharmaceuticals Ltd.

Prolong Pharmaceuticals, LLC

Richter Gedeon Nyrt.

Sandoz International GmbH

Neutropenia Drugs Segment by Type

Capsule

Injection

Neutropenia Drugs Segment by Application

Hospital

Clinic

Neutropenia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neutropenia Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neutropenia Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neutropenia Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Neutropenia Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neutropenia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neutropenia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neutropenia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neutropenia Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neutropenia Drugs industry.

Chapter 3: Detailed analysis of Neutropenia Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neutropenia Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neutropenia Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neutropenia Drugs Industry Trends Table 2. Neutropenia Drugs Industry Drivers Table 3. Neutropenia Drugs Industry Opportunities and Challenges Table 4. Neutropenia Drugs Industry Restraints Table 5. Global Neutropenia Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neutropenia Drugs Revenue Share by Company (2021-2026) Table 7. Global Neutropenia Drugs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Neutropenia Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Neutropenia Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Neutropenia Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neutropenia Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Neutropenia Drugs Company, Product Type & Application Table 13. Global Neutropenia Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neutropenia Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Capsule Table 18. Significant Companies of Injection Table 19. Global Neutropenia Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Neutropenia Drugs Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Neutropenia Drugs Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Neutropenia Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Neutropenia Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Neutropenia Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Neutropenia Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Neutropenia Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Neutropenia Drugs Sales Value Share by Type (2021-2026) Table 28. Global Neutropenia Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Neutropenia Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 32. Global Neutropenia Drugs Sales Volume by Application (2021-2026) & (Tons) Table 33. Global Neutropenia Drugs Sales Volume by Application (2027-2032) & (Tons) Table 34. Global Neutropenia Drugs Sales Volume Share by Application (2021-2026) Table 35. Global Neutropenia Drugs Sales Volume Share by Application (2027-2032) Table 36. Global Neutropenia Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Neutropenia Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Neutropenia Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Neutropenia Drugs Sales Value Share by Application (2021-2026) Table 40. Global Neutropenia Drugs Sales Value Share by Application (2027-2032) Table 41. Global Neutropenia Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 42. Global Neutropenia Drugs Sales by Region (2021-2026) & (Tons) Table 43. Global Neutropenia Drugs Sales Market Share by Region (2021-2026) Table 44. Global Neutropenia Drugs Sales by Region (2027-2032) & (Tons) Table 45. Global Neutropenia Drugs Sales Market Share by Region (2027-2032) Table 46. Global Neutropenia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Neutropenia Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Neutropenia Drugs Sales Value Share by Region (2021-2026) Table 49. Global Neutropenia Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Neutropenia Drugs Sales Value Share by Region (2027-2032) Table 51. Global Neutropenia Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 52. Global Neutropenia Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 53. Global Neutropenia Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 54. Global Neutropenia Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Neutropenia Drugs Sales by Country (2021-2026) & (Tons) Table 56. Global Neutropenia Drugs Sales Market Share by Country (2021-2026) Table 57. Global Neutropenia Drugs Sales by Country (2027-2032) & (Tons) Table 58. Global Neutropenia Drugs Sales Market Share by Country (2027-2032) Table 59. Global Neutropenia Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Neutropenia Drugs Sales Value Market Share by Country (2021-2026) Table 61. Global Neutropenia Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Neutropenia Drugs Sales Value Market Share by Country (2027-2032) Table 63. Apotex Inc. Company Information Table 64. Apotex Inc. Business Overview Table 65. Apotex Inc. Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 66. Apotex Inc. Neutropenia Drugs Product Portfolio Table 67. Apotex Inc. Recent Development Table 68. Biogenomics Limited Company Information Table 69. Biogenomics Limited Business Overview Table 70. Biogenomics Limited Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 71. Biogenomics Limited Neutropenia Drugs Product Portfolio Table 72. Biogenomics Limited Recent Development Table 73. Cellerant Therapeutics, Inc. Company Information Table 74. Cellerant Therapeutics, Inc. Business Overview Table 75. Cellerant Therapeutics, Inc. Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 76. Cellerant Therapeutics, Inc. Neutropenia Drugs Product Portfolio Table 77. Cellerant Therapeutics, Inc. Recent Development Table 78. Coherus BioSciences, Inc. Company Information Table 79. Coherus BioSciences, Inc. Business Overview Table 80. Coherus BioSciences, Inc. Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 81. Coherus BioSciences, Inc. Neutropenia Drugs Product Portfolio Table 82. Coherus BioSciences, Inc. Recent Development Table 83. Dr. Reddy’s Laboratories Limited Company Information Table 84. Dr. Reddy’s Laboratories Limited Business Overview Table 85. Dr. Reddy’s Laboratories Limited Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 86. Dr. Reddy’s Laboratories Limited Neutropenia Drugs Product Portfolio Table 87. Dr. Reddy’s Laboratories Limited Recent Development Table 88. Ligand Pharmaceuticals, Inc. Company Information Table 89. Ligand Pharmaceuticals, Inc. Business Overview Table 90. Ligand Pharmaceuticals, Inc. Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 91. Ligand Pharmaceuticals, Inc. Neutropenia Drugs Product Portfolio Table 92. Ligand Pharmaceuticals, Inc. Recent Development Table 93. NAL Pharmaceuticals Ltd. Company Information Table 94. NAL Pharmaceuticals Ltd. Business Overview Table 95. NAL Pharmaceuticals Ltd. Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 96. NAL Pharmaceuticals Ltd. Neutropenia Drugs Product Portfolio Table 97. NAL Pharmaceuticals Ltd. Recent Development Table 98. Prolong Pharmaceuticals, LLC Company Information Table 99. Prolong Pharmaceuticals, LLC Business Overview Table 100. Prolong Pharmaceuticals, LLC Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 101. Prolong Pharmaceuticals, LLC Neutropenia Drugs Product Portfolio Table 102. Prolong Pharmaceuticals, LLC Recent Development Table 103. Richter Gedeon Nyrt. Company Information Table 104. Richter Gedeon Nyrt. Business Overview Table 105. Richter Gedeon Nyrt. Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 106. Richter Gedeon Nyrt. Neutropenia Drugs Product Portfolio Table 107. Richter Gedeon Nyrt. Recent Development Table 108. Sandoz International GmbH Company Information Table 109. Sandoz International GmbH Business Overview Table 110. Sandoz International GmbH Neutropenia Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 111. Sandoz International GmbH Neutropenia Drugs Product Portfolio Table 112. Sandoz International GmbH Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Neutropenia Drugs Distributors List Table 116. Neutropenia Drugs Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Neutropenia Drugs Product Image Figure 2. Global Neutropenia Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neutropenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neutropenia Drugs Sales (2021-2032) & (Tons) Figure 5. Global Neutropenia Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Neutropenia Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Capsule Image Figure 10. Injection Image Figure 11. Global Neutropenia Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Neutropenia Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Neutropenia Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Neutropenia Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Neutropenia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Neutropenia Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Neutropenia Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 20. Global Neutropenia Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Neutropenia Drugs Sales Volume Share by Application (2021-2032) Figure 22. Global Neutropenia Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Neutropenia Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Neutropenia Drugs Sales Value Share by Application (2021-2032) Figure 25. Global Neutropenia Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 26. Global Neutropenia Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Neutropenia Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Neutropenia Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Neutropenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. North America Neutropenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Neutropenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Neutropenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Neutropenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Neutropenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Neutropenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. South America Neutropenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Neutropenia Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Neutropenia Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Neutropenia Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Neutropenia Drugs Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Neutropenia Drugs Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Capsule
  • Injection
Applications
  • Hospital
  • Clinic
Companies covered
  • Apotex Inc.
  • Biogenomics Limited
  • Cellerant Therapeutics, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy’s Laboratories Limited
  • Ligand Pharmaceuticals, Inc.
  • NAL Pharmaceuticals Ltd.
  • Prolong Pharmaceuticals, LLC
  • Richter Gedeon Nyrt.
  • Sandoz International GmbH

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neutropenia Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Neutropenia Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Neutropenia Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neutropenia Drugs Market Dynamics
  1. 2.1 Neutropenia Drugs Industry Trends
  2. 2.2 Neutropenia Drugs Industry Drivers
  3. 2.3 Neutropenia Drugs Industry Opportunities and Challenges
  4. 2.4 Neutropenia Drugs Industry Restraints
3 Neutropenia Drugs Market by Company
  1. 3.1 Global Neutropenia Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Neutropenia Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Neutropenia Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Neutropenia Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Neutropenia Drugs Company Ranking (2024-2026)
  6. 3.6 Global Neutropenia Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Neutropenia Drugs Company Product Type and Application
  8. 3.8 Global Neutropenia Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neutropenia Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neutropenia Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neutropenia Drugs Market by Type
  1. 4.1 Neutropenia Drugs Type Introduction
  2. 4.1.1 Capsule
  3. 4.1.2 Injection
  4. 4.2 Global Neutropenia Drugs Sales Volume by Type
  5. 4.2.1 Global Neutropenia Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Neutropenia Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Neutropenia Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Neutropenia Drugs Sales Value by Type
  9. 4.3.1 Global Neutropenia Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Neutropenia Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Neutropenia Drugs Sales Value Share by Type (2021-2032)
5 Neutropenia Drugs Market by Application
  1. 5.1 Neutropenia Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Neutropenia Drugs Sales Volume by Application
  5. 5.2.1 Global Neutropenia Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Neutropenia Drugs Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Neutropenia Drugs Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Neutropenia Drugs Sales Value by Application
  9. 5.3.1 Global Neutropenia Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Neutropenia Drugs Sales Value by Application (2021-2032)
  11. 5.3.3 Global Neutropenia Drugs Sales Value Share by Application (2021-2032)
6 Neutropenia Drugs Regional Sales and Value Analysis
  1. 6.1 Global Neutropenia Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neutropenia Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Neutropenia Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Neutropenia Drugs Sales by Region (2027-2032)
  5. 6.3 Global Neutropenia Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neutropenia Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neutropenia Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neutropenia Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Neutropenia Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neutropenia Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Neutropenia Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neutropenia Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Neutropenia Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neutropenia Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neutropenia Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neutropenia Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Neutropenia Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neutropenia Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neutropenia Drugs Sales Value Share by Country, 2025 VS 2032
7 Neutropenia Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Neutropenia Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neutropenia Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neutropenia Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Neutropenia Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Neutropenia Drugs Sales by Country (2027-2032)
  6. 7.4 Global Neutropenia Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neutropenia Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neutropenia Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neutropenia Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neutropenia Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neutropenia Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Apotex Inc.
  2. 8.1.1 Apotex Inc. Company Information
  3. 8.1.2 Apotex Inc. Business Overview
  4. 8.1.3 Apotex Inc. Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Apotex Inc. Neutropenia Drugs Product Portfolio
  6. 8.1.5 Apotex Inc. Recent Developments
  7. 8.2 Biogenomics Limited
  8. 8.2.1 Biogenomics Limited Company Information
  9. 8.2.2 Biogenomics Limited Business Overview
  10. 8.2.3 Biogenomics Limited Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Biogenomics Limited Neutropenia Drugs Product Portfolio
  12. 8.2.5 Biogenomics Limited Recent Developments
  13. 8.3 Cellerant Therapeutics, Inc.
  14. 8.3.1 Cellerant Therapeutics, Inc. Company Information
  15. 8.3.2 Cellerant Therapeutics, Inc. Business Overview
  16. 8.3.3 Cellerant Therapeutics, Inc. Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Cellerant Therapeutics, Inc. Neutropenia Drugs Product Portfolio
  18. 8.3.5 Cellerant Therapeutics, Inc. Recent Developments
  19. 8.4 Coherus BioSciences, Inc.
  20. 8.4.1 Coherus BioSciences, Inc. Company Information
  21. 8.4.2 Coherus BioSciences, Inc. Business Overview
  22. 8.4.3 Coherus BioSciences, Inc. Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Coherus BioSciences, Inc. Neutropenia Drugs Product Portfolio
  24. 8.4.5 Coherus BioSciences, Inc. Recent Developments
  25. 8.5 Dr. Reddy’s Laboratories Limited
  26. 8.5.1 Dr. Reddy’s Laboratories Limited Company Information
  27. 8.5.2 Dr. Reddy’s Laboratories Limited Business Overview
  28. 8.5.3 Dr. Reddy’s Laboratories Limited Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Dr. Reddy’s Laboratories Limited Neutropenia Drugs Product Portfolio
  30. 8.5.5 Dr. Reddy’s Laboratories Limited Recent Developments
  31. 8.6 Ligand Pharmaceuticals, Inc.
  32. 8.6.1 Ligand Pharmaceuticals, Inc. Company Information
  33. 8.6.2 Ligand Pharmaceuticals, Inc. Business Overview
  34. 8.6.3 Ligand Pharmaceuticals, Inc. Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Ligand Pharmaceuticals, Inc. Neutropenia Drugs Product Portfolio
  36. 8.6.5 Ligand Pharmaceuticals, Inc. Recent Developments
  37. 8.7 NAL Pharmaceuticals Ltd.
  38. 8.7.1 NAL Pharmaceuticals Ltd. Company Information
  39. 8.7.2 NAL Pharmaceuticals Ltd. Business Overview
  40. 8.7.3 NAL Pharmaceuticals Ltd. Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 NAL Pharmaceuticals Ltd. Neutropenia Drugs Product Portfolio
  42. 8.7.5 NAL Pharmaceuticals Ltd. Recent Developments
  43. 8.8 Prolong Pharmaceuticals, LLC
  44. 8.8.1 Prolong Pharmaceuticals, LLC Company Information
  45. 8.8.2 Prolong Pharmaceuticals, LLC Business Overview
  46. 8.8.3 Prolong Pharmaceuticals, LLC Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Prolong Pharmaceuticals, LLC Neutropenia Drugs Product Portfolio
  48. 8.8.5 Prolong Pharmaceuticals, LLC Recent Developments
  49. 8.9 Richter Gedeon Nyrt.
  50. 8.9.1 Richter Gedeon Nyrt. Company Information
  51. 8.9.2 Richter Gedeon Nyrt. Business Overview
  52. 8.9.3 Richter Gedeon Nyrt. Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Richter Gedeon Nyrt. Neutropenia Drugs Product Portfolio
  54. 8.9.5 Richter Gedeon Nyrt. Recent Developments
  55. 8.10 Sandoz International GmbH
  56. 8.10.1 Sandoz International GmbH Company Information
  57. 8.10.2 Sandoz International GmbH Business Overview
  58. 8.10.3 Sandoz International GmbH Neutropenia Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Sandoz International GmbH Neutropenia Drugs Product Portfolio
  60. 8.10.5 Sandoz International GmbH Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neutropenia Drugs Value Chain Analysis
  2. 9.1.1 Neutropenia Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neutropenia Drugs Sales Mode & Process
  6. 9.2 Neutropenia Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neutropenia Drugs Distributors
  9. 9.2.3 Neutropenia Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst